area of diabetic nephropathy. In September 2014, AstraZeneca plc and Eli Lilly and Co. announced that they reached a deal to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme or BACE inhibitor currently in development as a potential treatment for Alzheimer's disease. In October 2014, AstraZeneca and Pharmacyclics Inc. announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors. In November 2014, Isis Pharmaceuticals, Inc. and AstraZeneca announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively. In November 2014, AstraZeneca, Pharmacyclics Inc. and Janssen Research & Development LLC have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor, co-developed and co-commercialized by Pharmacyclics and Janssen Biotech Inc. History The company was founded 1992. It was incorporated in England and Wales in 1992 under the Companies Act 1985. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999.
astrazeneca plc-spons adr (AZNN:Mexico)
2 Kingdom Street
London, W2 6BD
Phone: 44 20 7604 8000
Fax: 44 20 7604 8151www.astrazeneca.com
|Biogen Idec Inc||$340.89 USD||+5.13|
|Bristol-Myers Squibb Co||$59.15 USD||-0.01|
|Celgene Corp||$109.60 USD||+3.48|
|Eli Lilly & Co||$70.16 USD||+0.42|
|Novo Nordisk A/S||kr260.80 DKK||-6.40|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.